Trevi Therapeutics, Inc. TRVI
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +8.31%
- 1 year
- +21.40%
- Open
- 13.78
- Prev close
- 13.81
- Mkt cap
- 1.93B
- Vol
- 1.73M
- Avg vol
- 1.95M
- EPS
- -0.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.44
- High
- 13.91
- Forward P/E
- -23.50
- Beta
- 0.98
- Short ratio
- 5.94
- Inst. own
- 109.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 14.79
- 200-d avg
- 14.33
- 1y target
- 28.18
5D chart
Signals (86)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 6 days ago |
News
5 days ago globenewswire.com
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET
-
2 weeks ago benzinga.com
Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with…
2 weeks ago globenewswire.com
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary…
2 weeks ago benzinga.com
Trevi Therapeutics Q2 2026 Earnings Call Transcript
Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
1 month ago seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
2 months ago globenewswire.com
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with…
2 months ago seekingalpha.com
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both…
-
2 months ago benzinga.com
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.
2 months ago marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights
Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,…
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
2 months ago seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Trevi Therapeutics Q2 EPS $(0.11), Inline
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the…
2 months ago globenewswire.com
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026
3 months ago globenewswire.com
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
3 months ago globenewswire.com
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn. , July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral…
3 months ago benzinga.com
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
3 months ago benzinga.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
-
3 months ago benzinga.com
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36
BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.
-
3 months ago benzinga.com
B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31
B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $31.
3 months ago benzinga.com
Global Payments To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on benzinga.com/analyst-stock-ratings
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.
3 months ago benzinga.com
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH)…
4 months ago globenewswire.com
Trevi Therapeutics Announces Upcoming June and July Event Schedule
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
5 months ago fool.com
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
-
5 months ago benzinga.com
Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.
5 months ago seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
5 months ago marketbeat.com
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
-
5 months ago benzinga.com
Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to $23.
5 months ago seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
Trevi Therapeutics Q1 2026 Earnings Call Transcript
Trevi Therapeutics Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last…
6 months ago globenewswire.com
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and…
6 months ago globenewswire.com
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup…
6 months ago globenewswire.com
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
6 months ago benzinga.com
What's Going On With Trevi Therapeutics Stock?
Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.
6 months ago benzinga.com
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Hastings' departure. Other stocks also dip in pre-market.
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 months ago benzinga.com
Why Blaize Holdings Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket
Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winmate for edge AI deployments. Other gainers & losers.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
6 months ago benzinga.com
Trevi Therapeutics Commences $150M Common Stock Offering
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients…
7 months ago benzinga.com
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings
Trevi Therapeutics reported a smaller loss in Q4, beating analyst estimates. Share price fell 2.5%. Analysts have mixed opinions on buying TRVI stock.
-
7 months ago benzinga.com
Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18
Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.
7 months ago benzinga.com
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright & Co, Stifel, BTIG, Goldman Sachs made changes.
-
7 months ago benzinga.com
Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.